NAT2*36 is assigned decreased function based on moderate evidence. NAT2*36 is characterized by the core SNVs c.403C>G (p.L135V), c.590G>A (p.R197Q), and c.803G>A (p.R268K). c.803G>A (p.R268K) defines NAT2*4, formerly considered the reference allele, which has repeatedly shown increased function in vivo and in vitro. There is no literature describing function for c.403C>G (p.L135V). Eight out of nine variant effect predictors tested by CPIC staff predict that c.403C>G is neutral/tolerated for protein function. c.590G>A (p.R197Q) defines NAT2*6 which has been extensively studied, exhibiting decreased N-acetyltransferase activity both in vivo and in vitro. Similarly, seven out of nine variant effect predictors tested by CPIC staff predict that c.590G>A impairs protein function. Thus, NAT2*36 is assigned decreased function based on c.590G>A. While c.403C>G is not predicted to impair protein function, it remains unknown whether there are any combinatorial effects associated with c.590G>A and c.403C>G.